Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Suven Life Sciences Business Update

Suven Life Sciences reported positive interim safety and analysis results for its Masupirdine Phase 3 study. The trial remains unchanged with enrollment completion expected by September 2026.

Source

NSE filing, NSE: SUVEN. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Suven Life Sciences Ltd: key numbers

Share price
₹268.05
Market cap
₹7,574 Cr
Revenue (annual)
₹7.11 Cr
Net profit (annual)
₹-276.3 Cr
P/E (TTM)
-21.5×Sector 52.0×
Promoter holding
65.47%-4.61% QoQ
FII holding
0.45%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Suven Life Sciences Ltd

All →

Other business update announcements

All →